We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+12.87%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$431M
AUM Growth
+$70.9M
Cap. Flow
+$79.1M
Cap. Flow %
18.34%
Top 10 Hldgs %
23.13%
Holding
178
New
54
Increased
29
Reduced
23
Closed
43

Top Buys

Rank Stock Value
1
XTNT icon
Xtant Medical Holdings
XTNT
+$14.7M
2
PALI icon
Palisade Bio
PALI
+$11M
3
POL.WS
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
+$10.1M
4
ECOR icon
electroCore
ECOR
+$8.6M
5
KLR
Kaleyra, Inc.
KLR
+$8.24M

Top Sells

Rank Stock Value
1
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$8.32M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.67M
3
STRO icon
Sutro Biopharma
STRO
+$5.16M
4
MBTCU
Nocturne Acquisition Corporation Unit
MBTCU
+$5M
5
IMNN icon
Imunon
IMNN
+$4.83M

Sector Composition

Rank Sector Weight
1 Healthcare 84.75%
2 Financials 3.74%
3 Technology 1.96%
4 Consumer Discretionary 0.54%
5 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PROF
51
Profound Medical
PROF
$307M
$3.44M 0.8%
210,280
+83,853
+66% +$1.56M
TCRR
52
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.43M 0.8%
209,130
– –
GKOS icon
53
Glaukos
GKOS
$10.1B
$3.43M 0.79%
40,400
-400
-1% -$32.8K
KRMD icon
54
KORU Medical Systems
KRMD
$196M
$3.37M 0.78%
+728,487
New +$2.86M
CRDF icon
55
Cardiff Oncology
CRDF
$73.1M
$3.34M 0.77%
+501,878
New +$4.26M
EYPT icon
56
EyePoint Inc
EYPT
$1B
$3.33M 0.77%
370,551
+81,235
+28% +$780K
TBPH icon
57
Theravance Biopharma
TBPH
$875M
$3.19M 0.74%
+220,000
New +$4.13M
XENT
58
DELISTED
Intersect ENT, Inc
XENT
$3.12M 0.72%
182,456
+40,600
+29% +$760K
CLDX icon
59
Celldex Therapeutics
CLDX
$3.09B
$3.11M 0.72%
93,116
+48,103
+107% +$1.32M
AVDL
60
DELISTED
Avadel Pharmaceuticals
AVDL
$2.96M 0.69%
440,589
– –
STIM icon
61
Neuronetics
STIM
$162M
$2.96M 0.69%
184,554
+47,054
+34% +$650K
XENE icon
62
Xenon Pharmaceuticals
XENE
$6.31B
$2.89M 0.67%
+155,000
New +$2.86M
PHAS
63
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.88M 0.67%
775,000
– –
HUMA icon
64
Humacyte
HUMA
$191M
$2.8M 0.65%
+275,000
New +$2.83M
INFI
65
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$2.79M 0.65%
934,327
-38,000
-4% -$120K
KALV
66
DELISTED
KalVista Pharmaceuticals
KALV
$2.68M 0.62%
111,834
-16,296
-13% -$426K
MLTX icon
67
MoonLake Immunotherapeutics
MLTX
$1.52B
$2.59M 0.6%
250,000
– –
TMPM
68
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$2.51M 0.58%
+254,000
New +$2.5M
SNCE
69
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.5M 0.58%
12,500
– –
MCRB icon
70
Seres Therapeutics
MCRB
$54.5M
$2.5M 0.58%
5,231
– –
TVTX icon
71
Travere Therapeutics
TVTX
$5.79B
$2.49M 0.58%
170,484
-40,000
-19% -$789K
ADMS
72
DELISTED
Adamas Pharmaceuticals
ADMS
$2.49M 0.58%
470,949
+20,949
+5% +$108K
RGNX icon
73
Regenxbio
RGNX
$660M
$2.42M 0.56%
+62,317
New +$2.23M
SRGA
74
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$2.42M 0.56%
+57,971
New +$2.97M
SRSAU
75
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
$2.35M 0.54%
225,000
– –
1 2
3
4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
GC
Gruss & Co West Palm Beach, Florida $42.8M AUM 49.41% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return

Altium Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Altium Capital Management held 178 positions worth $431M, up 20% from $360M the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Altium Capital Management deployed $79.1M of net new capital in Q2 2021, opening 54 new positions and adding to 29 existing holdings. Its largest new stake was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Verastem, an estimated $2.98M trimmed.

  • Altium Capital Management's largest Q2 2021 buy was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.
  • Altium Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2021, an estimated $7.41M increase.
  • Altium Capital Management's biggest Q2 2021 reduction was Verastem, cutting an estimated $2.98M.
  • Altium Capital Management fully exited Biora Therapeutics, Inc. Common Stock in Q2 2021, selling an estimated $8.32M.
  • Altium Capital Management's ten largest holdings make up 23% of its $431M portfolio in Q2 2021.
  • Altium Capital Management opened 54 new positions and closed 43 in Q2 2021.
  • Altium Capital Management's portfolio value rose 20% quarter-over-quarter to $431M.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.